CD19 and lymphoma: B-lymphoblastic leukemia/lymphoma with KMT2A rearrangement typically has a CD19-positive, CD10-negative, CD24-negative, and TdT-negative immunophenotype, as well as positivity for myeloid markers CD15 and CD65.